Search research articles
Contact Us
Filters
Showing results (411-420 of 491) with videos related to
Page
of 50
Sort By:
Nature Reviews. Disease Primers
|
February 20, 2025
Bullous pemphigoid
Hossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
Advances in Therapy
|
March 5, 2024
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
Dédée F Murrell, Pascal Joly, Victoria P Werth, et al.
Advances in Therapy
|
May 24, 2024
Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
Dédée F Murrell, Pascal Joly, Victoria P Werth, et al.
Dermatologic Therapy
|
October 6, 2022
Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab-treated and rituximab-naïve patients
Elham Mazaherpour, Nika Kianfar, Shayan Dasdar, et al.
Survey of Ophthalmology
|
February 19, 2022
Dupilumab-associated ocular manifestations: A review of clinical presentations and management
Duoduo Wu, Benjamin S Daniel, Andre J X Lai, et al.
The Journal of Investigative Dermatology
|
March 17, 2024
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study
Dedee F Murrell, Frédéric Caux, Aikaterini Patsatsi, et al.
JAAD International
|
August 19, 2021
A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)
Clare L Rogers, Matthew Gibson, Johannes S Kern, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 5, 2022
Proposed management algorithm for dupilumab-associated ocular side effects: a collaborative effort between dermatologists and ophthalmologists
D Wu, B S Daniel, A J X Lai, et al.
The British Journal of Dermatology
|
May 7, 2020
Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores
L Ferries, A Gillibert, S Duvert-Lehembre, et al.
The British Journal of Dermatology
|
September 19, 2025
Navigating challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey
Eva W H Korte, Marjolein A J Hiel, Maria C Bolling, et al.
Page
of 50
Search research articles
Search
Showing results (411-420 of 491) with videos related to
Sort By:
Page
of 50
Nature Reviews. Disease Primers
|
February 20, 2025
Bullous pemphigoid
Hossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, et al.
Advances in Therapy
|
March 5, 2024
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
Dédée F Murrell, Pascal Joly, Victoria P Werth, et al.
Advances in Therapy
|
May 24, 2024
Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
Dédée F Murrell, Pascal Joly, Victoria P Werth, et al.
Dermatologic Therapy
|
October 6, 2022
Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab-treated and rituximab-naïve patients
Elham Mazaherpour, Nika Kianfar, Shayan Dasdar, et al.
Survey of Ophthalmology
|
February 19, 2022
Dupilumab-associated ocular manifestations: A review of clinical presentations and management
Duoduo Wu, Benjamin S Daniel, Andre J X Lai, et al.
The Journal of Investigative Dermatology
|
March 17, 2024
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study
Dedee F Murrell, Frédéric Caux, Aikaterini Patsatsi, et al.
JAAD International
|
August 19, 2021
A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)
Clare L Rogers, Matthew Gibson, Johannes S Kern, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 5, 2022
Proposed management algorithm for dupilumab-associated ocular side effects: a collaborative effort between dermatologists and ophthalmologists
D Wu, B S Daniel, A J X Lai, et al.
The British Journal of Dermatology
|
May 7, 2020
Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores
L Ferries, A Gillibert, S Duvert-Lehembre, et al.
The British Journal of Dermatology
|
September 19, 2025
Navigating challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey
Eva W H Korte, Marjolein A J Hiel, Maria C Bolling, et al.
Page
of 50